135 related articles for article (PubMed ID: 21164349)
1. Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study.
Al Rifai A; Prasad N; Shuttleworth E; McBurney H; Pushpakom S; Robinson A; Newman W; Campbell S
Eur J Gastroenterol Hepatol; 2011 Feb; 23(2):153-8. PubMed ID: 21164349
[TBL] [Abstract][Full Text] [Related]
2. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine.
Seksik P; Cosnes J; Sokol H; Nion-Larmurier I; Gendre JP; Beaugerie L
Aliment Pharmacol Ther; 2009 May; 29(10):1106-13. PubMed ID: 19222411
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.
Vögelin M; Biedermann L; Frei P; Vavricka SR; Scharl S; Zeitz J; Sulz MC; Fried M; Rogler G; Scharl M
PLoS One; 2016; 11(5):e0155218. PubMed ID: 27214202
[TBL] [Abstract][Full Text] [Related]
4. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
5. Onychomycosis in inflammatory bowel diseases.
Gaburri D; Chebli JM; Zanine A; Gamonal AC; Gaburri PD
J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):807-12. PubMed ID: 18435735
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
[TBL] [Abstract][Full Text] [Related]
7. Review article: Reproduction in the patient with inflammatory bowel disease.
Heetun ZS; Byrnes C; Neary P; O'Morain C
Aliment Pharmacol Ther; 2007 Aug; 26(4):513-33. PubMed ID: 17661756
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
[TBL] [Abstract][Full Text] [Related]
9. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
Daperno M; Sostegni R; Canaparo R; Serpe L; Lavagna A; Crocellà L; Castagno F; Vernetto A; Rigazio C; Ercole E; D'Antico S; Pera A; Zara G; Rocca R
Aliment Pharmacol Ther; 2009 Oct; 30(8):843-53. PubMed ID: 19650826
[TBL] [Abstract][Full Text] [Related]
11. Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment.
Steel AW; Mela CM; Lindsay JO; Gazzard BG; Goodier MR
Aliment Pharmacol Ther; 2011 Jan; 33(1):115-26. PubMed ID: 21083588
[TBL] [Abstract][Full Text] [Related]
12. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
Su C; Lichtenstein GR
Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
[TBL] [Abstract][Full Text] [Related]
13. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease.
Smith MA; Marinaki AM; Arenas M; Shobowale-Bakre M; Lewis CM; Ansari A; Duley J; Sanderson JD
Aliment Pharmacol Ther; 2009 Aug; 30(4):375-84. PubMed ID: 19500084
[TBL] [Abstract][Full Text] [Related]
14. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis.
Bermejo F; Lopez-Sanroman A; Taxonera C; Gisbert JP; Pérez-Calle JL; Vera I; Menchén L; Martín-Arranz MD; Opio V; Carneros JA; Van-Domselaar M; Mendoza JL; Luna M; López P; Calvo M; Algaba A
Aliment Pharmacol Ther; 2008 Sep; 28(5):623-8. PubMed ID: 18513380
[TBL] [Abstract][Full Text] [Related]
15. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
[TBL] [Abstract][Full Text] [Related]
17. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease.
de Fonclare AL; Khosrotehrani K; Aractingi S; Duriez P; Cosnes J; Beaugerie L
Arch Dermatol; 2007 Jun; 143(6):744-8. PubMed ID: 17576940
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
19. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
